Literature DB >> 21418251

Case fatality in children with supraventricular tachycardia in the United States.

Jack C Salerno1, Michelle M Garrison, Cindy Larison, Stephen P Seslar.   

Abstract

BACKGROUND: The prognosis for most patients with supraventricular tachycardia (SVT) is thought to be excellent. However, the fatality rate in children with SVT is poorly defined and there are no large-scale, multicenter studies to support this commonly held belief.
METHODS: We reviewed an administrative database containing inpatient records from 41 stand-alone children's hospitals and identified all hospitalized patients younger than 25 years with a discharge diagnosis of SVT between January 2003 and September 2008.
RESULTS: We analyzed the index hospitalization of 1,755 patients with the discharge diagnosis of SVT, of whom 58% were male and 52% had comorbid structural heart disease (SHD). There were a total of 68 patient deaths (4%) with 56 of 68 (82%) of the deaths occurring in patients with SHD. In total, 6% of the patients with SHD died, whereas only 1% of the patients without SHD died. Regression analysis revealed that case fatality is increased in patients less than 1 month of age (OR 2.41, 95% CI 1.35 to 4.32), in patients with SHD (OR 2.67, 95% CI 1.22 to 5.80), and in those having cardiomyopathy with (OR 6.72, 95% CI 1.79 to 25.28) and without SHD (OR 6.74, 95% CI 1.67 to 27.26).
CONCLUSIONS: The case fatality in patients who have SVT without SHD is low. It is increased in the very young and in those with comorbid cardiovascular disease. Case fatality is highest in patients with a cardiomyopathy regardless of SHD. ©2011, The Authors. Journal compilation ©2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21418251     DOI: 10.1111/j.1540-8159.2011.03073.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

1.  Factors associated with the occurrence and treatment of supraventricular tachycardia in a pediatric congenital heart disease cohort.

Authors:  Avnish Tripathi; George B Black; Yong-Moon Mark Park; Jeanette M Jerrell
Journal:  Pediatr Cardiol       Date:  2013-09-01       Impact factor: 1.655

2.  Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children.

Authors:  Johannes C von Alvensleben; Martin J LaPage; Regine Caruthers; David J Bradley
Journal:  Pediatr Cardiol       Date:  2016-12-19       Impact factor: 1.655

3.  Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database.

Authors:  Patricia Y Chu; Kevin D Hill; Reese H Clark; P Brian Smith; Christoph P Hornik
Journal:  Early Hum Dev       Date:  2015-04-28       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.